A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants with Smoldering Multiple Myeloma

Update Il y a 4 ans
Reference: EUCTR2014-005139-14

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

- To evaluate if daratumumab can effectively decrease M protein in subjects with intermediate or high-risk SMM as assessed by CR rate - To determine if daratumumab reduces the progression/death rate in subjects with intermediate or high-risk SMM


Inclusion criteria

  • Smoldering multiple myeloma